Basilea Pharmaceutica AG entered a worldwide agreement with Johnson & Johnson subsidiary Cilag AG International for the development, manufacturing and marketing of its cephalosporin antibiotic ceftobiprole, which is undergoing a Phase III trial in patients with complicated skin and skin-structure infections. (BioWorld International)